Table 3.

Odds of structural damage progression for different factors

	Odds ratio	Lower 95% CI	Upper 95% CI	p value
Baricitinib 4 mg vs MTX	0.57	0.31	1.04	0.066
Baricitinib 4 mg + MTX vs MTX	0.32	0.17	0.61	< 0.001
Age	1.00	0.98	1.02	0.820
Sex (female vs male)	2.28	1.17	4.44	0.015
Duration of RA	0.95	0.87	1.05	0.322
Baseline BMI	0.94	0.89	0.99	0.025
ACPA positive (vs negative)	1.19	0.42	3.41	0.745
RF positive (vs negative)	1.76	0.20	15.06	0.608
Smoker (yes vs no)	1.92	1.04	3.56	0.037
Baseline hsCRP	1.02	1.01	1.03	< 0.001
Baseline HAQ-DI	0.70	0.45	1.09	0.111
Baseline mTSS	1.00	0.99	1.02	0.319
Baseline CDAI	1.03	1.00	1.05	0.038
Baseline joint erosions (positive vs negative)	1.44	0.80	2.59	0.224

Odds ratios were estimated using a multivariate logistic regression model adjusted for baseline factors. Factors significantly associated with an increased or decreased risk of structural damage progression are shown in bold

ACPA anti-citrullinated protein antibody, BMI body mass index, CDAI Clinical Disease Activity Index, CI confidence interval, HAQ-DI Health Assessment Questionnaire-Disability Index, hsCRP high-sensitivity C-reactive protein, mTSS van der Heijde-modified total Sharp score, MTX methotrexate, RA rheumatoid arthritis, RF rheumatoid factor